Medical records may be private information, but a patient's genes belong to the entire family. And that raises a quandary for medical researchers: When they find something troubling in a subject's genome, should they pass it along to the family? Even after the patient dies?
Dozens of the nation's top researchers, bioethicists and federal health officials gathered Thursday at the University of Minnesota in an effort to answer those questions and offer guidelines for ethics dilemmas created by the burgeoning field of genomic research.
In a recent survey, cancer patients were asked to consider the case of a hypothetical patient named "Pat" who was diagnosed with pancreatic cancer in 2009 and enrolled in a research project at the Mayo Clinic. Three years later, researchers running tests on Pat's blood discovered a mutation with strong links to breast cancer. Should they inform Pat's 22-year-old daughter so she can get regular cancer screening? Should other relatives be told that Pat carried a gene now linked to pancreatic cancer? What if Pat wanted the research results kept private, but has since died?
Breakthroughs in genomic testing allow researchers to uncover risks with serious health implications for a subject's biological relatives, but U.S. law and research rules assiduously protect the privacy of research subjects, said Susan Wolf, founding chair of the U's Consortium on Law and Values in Health, Environment & the Life Sciences, which hosted the conference.
In addition, genomic research often carries on for years — long after individual study participants have died. Relatives are curious, but the federal Health Insurance Portability and Accountability Act (HIPAA) preserves the privacy of an individual's medical and laboratory records for 50 years after their death, though it allows some exceptions.
"So there is this tension," Wolf said. "We have to anticipate, what are we going to do with all of this information after the death of a participant?"
Wolf is one of three principal investigators among the U, the Mayo Clinic and the University of California, San Francisco (UCSF) who are spearheading a $2.4 million project funded by the National Institutes of Health to guide the disclosure of "incidental findings" in genomic research.
Wolf and her 15 collaborators presented their preliminary recommendations Thursday at the U. They plan to produce a final report to be published next year in the Journal of Law, Medicine & Ethics.